The Covid-19 pandemic gave big pharma big payday. But it also caused the industry to rethink a globalized supply chain centered on Asia. What will it take to reshore at least some generic drugs to the U.S.
Can the U.S. really bring manufacturing home? A McKinsey study shows that existing concentration of some supply chains will make it hard. Here’s what needs to be done.
Arizona gets $60 million solar plant. But the owner is China’s JA Solar, a company that will be in the cross hairs of forced labor laws.
Canadian Solar is mostly Chinese-run and produced. Its solar panels in a Maine government project may be tainted by forced labor.
A Department of Energy official warns that China’s outsized role in the solar industry is a headwind for Biden’s green energy plans, and energy security.
The November trade deficit fell, but that didn’t stop the U.S. from record imports this year. The goods deficit is now over $1.1 trillion.
A Senate Commerce subcommittee hearing heard from witnesses who said worker shortages will ultimately be a drag on U.S. reshoring efforts. Pharmaceutical reps warned of high energy costs, which could add to import dependence.
One of India’s pharmaceutical labs has run afoul of the FDA many times this year. The U.S. is dependent on foreign labs like Aurobindo for its drug supply. Can the government help change that?
As 2022 winds down, one thing remains clear, globalization is losing support among policy makers, and even among influencers like Paul Krugman.
The State Department awarded subsidiaries of The Gap in India and Intel in Costa Rica for actions taken by those companies there. Here’s why the parent companies never would have qualified.
